Cytosorbents Corporation (CTSO) Stock Score, Valuation & Financial Research
Cytosorbents Corporation is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 17/100.
Quick answer for CTSO
Cytosorbents Corporation currently has a Wall Street Score of 17/100. The stored market price is $5.73. Its financial score is 21/100. Its valuation score is 0/100. The latest WSS change is +0.7 points. These figures are a research snapshot, not a buy or sell recommendation.
What Cytosorbents Corporation does
Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants
CTSO financial snapshot
- Wall Street Score:
- 17/100
- Current price:
- $5.73
- Market capitalization:
- $18.0M
- Revenue:
- $37.2M
- Net income:
- $-18.2M
- Free cash flow:
- $-12.5M
- Cash:
- $4.4M
- Total debt:
- $26.3M
- EPS:
- -5.75
- Financial score:
- 21/100
- Valuation score:
- 0/100
- Revenue score:
- 28/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-12.5M, showing cash burn in the current stored period.
- The balance sheet shows $4.4M of cash versus $26.3M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.7 points: CTSO increased 0.7 points because Revenue improved by 3.1 points, Asset improved by 3.7 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 21/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research CTSO
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.